Pathogenic utoantibodies often return following treatment in systemic lupus erythematosus (SLE), suggesting that long-lived plasma cells (PC) are not sensitive to such interventions. Therefore, their elimination is a key therapeutic goal in treatment. The goal of these studies is to validate P-selection glycoprotein ligand-1 (PSGL-1) as a novel marker for plasma cells in lupus, and as a therapeutic target in SLE. This work is based upon the observation that a subset of B cells differentiating into antibody secreting cells in germinal centers, the site of B cell memory and PC formation, express PSGL-1, with its expression highly upregulated on PC. The hypothesis to be tested is that PSGL-1 expression on antibody-secreting cells plays an important role in their trafficking to the bone marrow and splenic red pulp, niches for their survival. To address this hypothesis, three specific aims are planned. First, PSGL-1 expression and function on PC in normal mice following immunization will be assessed. Next, similar studies will be carried in lupus-prone mice, followed by blockade of PSGL1 interactions with its ligands, asking if PC trafficking to survival niches is altered, leading to diminished survival. Finally, PSGL- 1+CD38hi PC will be characterized in the peripheral blood of lupus patients, correlating their numbers with disease activity in an effort to support the idea that PSGL-1 on PC is an appropriate therapeutic target in SLE.

Public Health Relevance

B cells that produce antibodies in the spleen and other lymphoid organs are critical for normal and autoimmune responses. Much remains to be learned about the biology of these cells in autoimmunity, including the requirements for their maturation and function, and how to block the latter as a potential therapy for autoimmune diseases. The results of the proposed studies should help address these issues, and advance knowledge of how autoimmune responses develop in humans and how they can be abrogated therapeutically.

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Exploratory/Developmental Grants (R21)
Project #
Application #
Study Section
Hypersensitivity, Autoimmune, and Immune-mediated Diseases Study Section (HAI)
Program Officer
Mancini, Marie
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Yale University
Internal Medicine/Medicine
Schools of Medicine
New Haven
United States
Zip Code
Ray, John P; Marshall, Heather D; Laidlaw, Brian J et al. (2014) Transcription factor STAT3 and type I interferons are corepressive insulators for differentiation of follicular helper and T helper 1 cells. Immunity 40:367-77
Weinstein, Jason S; Bertino, Sarah A; Hernandez, Sairy G et al. (2014) B cells in T follicular helper cell development and function: separable roles in delivery of ICOS ligand and antigen. J Immunol 192:3166-79
Bertino, Sarah A; Craft, Joe (2013) Roquin paralogs add a new dimension to ICOS regulation. Immunity 38:624-6